Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road South West
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
E: sarah@resverlogix.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
18
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,416.60 | 57.70 | -0.68% |
CAC 40 | 7,541.36 | 63.58 | 0.85% |
DAX 40 | 19,120.93 | 105.52 | 0.55% |
Dow JONES (US) | 42,352.75 | 341.16 | 0.81% |
FTSE 100 | 8,280.63 | 1.89 | -0.02% |
HKSE | 22,736.87 | 623.36 | 2.82% |
NASDAQ | 18,137.85 | 219.37 | 1.22% |
Nikkei 225 | 38,635.62 | 83.56 | 0.22% |
NZX 50 Index | 12,619.94 | 47.28 | 0.38% |
S&P 500 | 5,751.07 | 51.13 | 0.90% |
S&P/ASX 200 | 8,150.00 | 55.20 | -0.67% |
SSE Composite Index | 3,336.50 | 248.97 | 8.06% |